Optimization Of Hiv Specific Immune Responses In Vivo

体内 HIV 特异性免疫反应的优化

• 批准号: 6684235
• 负责人: ROBERT A SEDER
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6684235
• 关键词: AIDS vaccines; Primates; Rodentias; T lymphocyte; cellular immunity; enzyme linked immunosorbent assay; human immunodeficiency virus 1; immunization; immunoregulation; leukocyte activation /transformation; tissue /cell culture; vaccine development; vector vaccine

Successful development of a vaccine against HIV will likely require the induction of both antibody and/or cellular immune responses sufficient to prevent infection or disease respectively following infectious challenge. While the induction of antibody responses for a variety of other infectious pathogens is readily achieved by a variety of vaccine formulations, live attenuated, recombinant viral vaccines or plasmid DNA vaccines only induce the induction of long-lived cellular immune responses, particularly CD8+ T cell responses. Moreover, since live attenuated HIV vaccines might be precluded from use due to safety concerns and DNA vaccines at present only induce modest CD8+ T cell responses in humans, there is an urgent need to develop ways to enhance the generation and maintenance of CD8+ T cell responses in humans in following immunization. This study focuses on how to optimize the magnitude and duration of CD8+ T cell responses following vaccination in rodents and primates using a variety of vaccine formulations.

成功开发抗 HIV 疫苗可能需要诱导抗体和/或细胞免疫反应，足以分别预防感染攻击后的感染或疾病。虽然通过多种疫苗制剂可以很容易地诱导针对多种其他感染性病原体的抗体反应，但减毒活重组病毒疫苗或质粒DNA疫苗只能诱导长效细胞免疫反应，特别是CD8+T细胞反应。此外，由于出于安全考虑，HIV减毒活疫苗可能被禁止使用，而DNA疫苗目前只能在人体中诱导适度的CD8+T细胞反应，因此迫切需要开发在免疫接种后增强人体CD8+T细胞反应的产生和维持的方法。本研究的重点是如何优化啮齿动物和灵长类动物使用各种疫苗配方接种疫苗后 CD8+ T 细胞反应的程度和持续时间。